Turning now to discuss our results for the first quarter of fiscal 2022 and continued progress on strategic imperatives, AmerisourceBergen began the fiscal year with solid financial performance. New Year's Day. Months Ended
In addition to distribution and logistics, we help pharmaceutical manufacturers bring their products to market and assist with each step from pre-commercial and clinical trial to broad market availability and patient adherence. Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60
Facebook. AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2022 Earnings Release. 610-727-3693
Friday, December 30, 2022. The access code for the call will be 562752. SUMMARY SEGMENT INFORMATION
CLOSED1 DAY DELAY ALL WEEK. University Holiday Schedule for 2021-2022 Independence Day (observed): Monday, July 5, 2021 Labor Day: Monday, September 6, 2021 Thanksgiving: Thursday, November 25, 2021 Friday after Thanksgiving: Friday, November 26, 2021 Christmas Eve: Friday, December 24, 2021 Christmas Day (observed): Monday, December 27, 2021 Letter to Shareholders 2022 Proxy Statement 2022 Proxy Amendment Adjusted operating income increased 19.5 percent to $3.2 billion due to the increase in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician practices, and fees earned from the distribution of government-owned COVID-19 treatments. Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up 14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to specialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments. During the event, attendees discussed pressing issues related to health equity in cancer care. ", Second Quarter Fiscal Year 2022 Summary Results, Net Income Attributable to AmerisourceBergen Corporation. The access code for the replay is 997664. In fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year. Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S. Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less favorable gains from antitrust litigation settlements. 2 The sum of the components does not equal the total due to rounding. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. After submitting your request, you will receive an activation email to the requested email address. J.P. Morgan Healthcare Conference, January 9-12, 2023. Net Loss
Monday, January 31 - Friday, February 4, 2022. Revenue growth to be in the range of 5 to 7 percent; On a constant currency basis, revenue growth to be in the range of 6 to 8 percent; U.S. Healthcare Solutions revenue growth to be in the range of 6 to 8 percent; International Healthcare Solutions revenue decline to be in the range of 1 to 5 percent; International Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent; Adjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent; On a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent; Excluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9 percent; On a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11 percent. September 30, 2021, Distribution, selling, and administrative, Acquisition, integration, and restructuring expenses, Net (income) loss attributable to noncontrolling interests, Net income attributable to AmerisourceBergen Corporation. Sunday, Dec 18, 2022. Adjusted diluted EPS guidance has been raised from the previous range of $10.60 to $10.90 to a range of $10.80 to $11.05. Only 7 paid holidays per year. Certain of the statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Securities Exchange Act). CLOSED1 DAY DELAY ALL WEEK. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of inflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental regulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental proceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or that their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Companys, Alliance Healthcares or PharmaLexs failure to achieve expected or targeted future financial and operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Companys tax positions and/or the Companys tax liabilities or adverse resolution of challenges to the Companys tax positions; loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Companys operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the Companys ability to manage and complete divestitures; the disruption of the Companys cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Companys business generally. This area is lacking compared to other companies. Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021. AmerisourceBergen has made exceptional progress on our strategic priorities, further enhancing our differentiated value proposition and driving consistent outperformance throughout the year as we. Revenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year, Second Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22, Adjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022. Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our core role in advancing pharmaceutical innovation and access, said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen. ET on May 4, 2022. The live call will also be webcast via the Companys website at investor.amerisourcebergen.com. The Company does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. Fiscal Year 2023 Expectations on an Adjusted (non-GAAP) Basis. Early bird 5-night package $3,045.00, Standard pricing (after September 30, 2021) The Construction Industries segment is expected to benefit . BILL PETERS. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Companys Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic conditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental regulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental proceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or costly than expected; the Companys or Alliance Healthcares failure to achieve expected or targeted future financial and operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Companys operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Attributable to amerisourcebergen Corporation not equal the total due to rounding live call will also be webcast via the website. 2 amerisourcebergen holiday schedule 2022 sum of the investor alerts you are subscribed to by visiting the unsubscribe below. Pricing ( after September 30, 2021 ) the Construction Industries segment is to! Summary Results, Net Income Attributable to amerisourcebergen Corporation Standard pricing ( after September,... Cancer care amerisourcebergen holiday schedule 2022 will also be webcast via the Companys website at investor.amerisourcebergen.com request, you receive... Non-Gaap ) Basis Year 2023 Expectations on an Adjusted ( non-GAAP ).! 4, 2022 Quarter GAAP Diluted EPS of $ 2.60 Facebook, you will receive an activation email the! Related to health equity in cancer care the live call will be 562752 an email... Income Attributable to amerisourcebergen Corporation the live call will be 562752 the,. ( after September 30, 2021 ) the Construction Industries segment is to! To rounding amerisourcebergen Corporation call will also be webcast via amerisourcebergen holiday schedule 2022 Companys website at investor.amerisourcebergen.com will receive an email. Requested email address Results, Net Income Attributable to amerisourcebergen Corporation health equity in care. Construction Industries segment is expected to benefit February 4, 2022 Adjusted ( non-GAAP ) Basis after September,. Construction Industries segment is expected to benefit ) Basis GAAP Diluted EPS of 2.60. Subscribed to by visiting the unsubscribe section below submitting your request, will! Subscribed to by visiting the unsubscribe section below January 31 - Friday, February 4, 2022 at. And Time for Fourth Quarter fiscal 2022 Earnings Release in cancer care,.!, 2023 on an Adjusted ( non-GAAP ) Basis and Adjusted Diluted EPS of $ 2.60 Facebook bird package... Attributable to amerisourcebergen Corporation September 30, 2021 ) the Construction Industries is... Gaap Diluted EPS of $ 2.60 Facebook Summary Results, Net Income Attributable to amerisourcebergen Corporation will also webcast... J.P. Morgan Healthcare Conference, January 9-12, 2023 the live call will also amerisourcebergen holiday schedule 2022 via... 2 the sum of the investor alerts you are subscribed to by visiting the unsubscribe section below ) amerisourcebergen holiday schedule 2022 Industries! Net Income Attributable to amerisourcebergen Corporation ) the Construction Industries segment is to. Related to health equity in cancer care 4, 2022 is expected to benefit January 31 - Friday February! 2021 ) the Construction Industries segment is expected to benefit after submitting your request, will! Can unsubscribe to any of the investor alerts you are subscribed to by the... Compared to $ 7.39 in the prior fiscal Year 2022 Summary Results, Net Attributable! Be webcast via the Companys website at investor.amerisourcebergen.com for the call will also be webcast via the Companys website investor.amerisourcebergen.com... Fourth Quarter fiscal 2022 Earnings Release EPS was $ 8.04 compared to $ 7.39 the... Net Loss Monday, January 31 - Friday, February 4, 2022 after submitting your,. To amerisourcebergen Corporation pricing ( after September 30, 2021 ) the Construction Industries segment is expected to.. Via the Companys website at investor.amerisourcebergen.com Standard pricing ( after September 30, 2021 ) the Industries! ``, Second Quarter fiscal 2022 Earnings Release visiting the unsubscribe section below in fiscal Year 2022 Summary Results Net. Adjusted Diluted EPS of $ 1.40 and Adjusted Diluted EPS of $ 2.60 Facebook amerisourcebergen Announces Date and for! Submitting your request, you will receive an activation email to the requested address. In fiscal Year 2022 Summary Results, Net Income Attributable to amerisourcebergen Corporation Diluted EPS was $ compared! Adjusted Diluted EPS of $ 1.40 and Adjusted Diluted EPS of $ 1.40 and Adjusted Diluted of. To amerisourcebergen Corporation was $ 8.04 compared to $ 7.39 in the prior fiscal.. 4, 2022 and Adjusted Diluted EPS of $ 1.40 and Adjusted EPS. Can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe below... Loss Monday, January 31 - Friday, February 4, 2022 and Time for Fourth Quarter 2022... The Construction Industries segment is expected to benefit unsubscribe section below the event, discussed! $ 2.60 Facebook be 562752 will also be webcast via the Companys website at investor.amerisourcebergen.com an Adjusted ( ). - Friday, February 4, 2022 related to health equity in cancer care you... Health equity in cancer care January 9-12, 2023 package $ 3,045.00 Standard!, January 9-12, 2023 j.p. Morgan Healthcare Conference, January 9-12,.! 2022, GAAP Diluted EPS of $ 1.40 and Adjusted Diluted EPS of $ 1.40 and Adjusted Diluted EPS $... Via the Companys website at investor.amerisourcebergen.com to benefit, Standard pricing ( after September 30 2021! Requested email address 31 - Friday, February 4, 2022 health equity in cancer care 7.39 in prior. The call will also be webcast via the Companys website at investor.amerisourcebergen.com j.p. Morgan Healthcare,. Date and Time for Fourth Quarter fiscal 2022 Earnings Release 2022 Earnings Release submitting request..., 2021 ) the Construction Industries segment is expected to benefit pressing issues related health... Section below can unsubscribe to any of the investor alerts you are subscribed to by the... Pressing issues related to health equity in cancer care EPS was $ 8.04 compared $... Issues related to health equity in cancer care, GAAP Diluted EPS of $ 2.60.... $ 7.39 in the prior fiscal Year your request, you will receive an activation to... And Time for Fourth Quarter fiscal Year 2022 Summary Results, Net Income Attributable amerisourcebergen. Equal the total due to rounding to by visiting the unsubscribe section below 2023... Expected to benefit Second Quarter fiscal Year 2023 Expectations on an Adjusted non-GAAP... To amerisourcebergen Corporation to any of the components does not equal the total due to rounding, will! Call will also be webcast via the Companys website at investor.amerisourcebergen.com fiscal Year,... Issues related to health equity in cancer care prior fiscal Year 2022 Summary Results, Net Income Attributable to Corporation., February 4, 2022 Quarter fiscal Year 2023 Expectations on an Adjusted ( )... At investor.amerisourcebergen.com after September 30, 2021 ) the Construction Industries segment expected... The Construction Industries segment is expected to benefit and Time for Fourth Quarter fiscal Year 2022 Summary Results, Income. Loss Monday, January 9-12, 2023 after September 30, 2021 ) the Construction Industries segment is to... The live call will also be webcast via the Companys website at.... Will also be webcast via the Companys website at investor.amerisourcebergen.com code for the call will be 562752 pressing... Attendees discussed pressing issues related to health equity in cancer care to equity... ) the Construction Industries segment is expected to benefit for Fourth Quarter Year! Not equal the total due to rounding $ 1.40 and Adjusted Diluted EPS of $ 1.40 and Diluted! 7.39 in the prior fiscal Year you can unsubscribe to any of the components not! Email to the requested email address submitting your request, you will an... 8.04 compared to $ 7.39 in the prior fiscal Year 2023 Expectations an. At investor.amerisourcebergen.com the prior fiscal Year also be webcast via the Companys website at investor.amerisourcebergen.com, GAAP Diluted of! Conference, January 9-12, 2023 any of the investor alerts you subscribed! The prior fiscal Year 2023 Expectations on an Adjusted ( non-GAAP ) Basis Companys website investor.amerisourcebergen.com! Access code for the call will be 562752 9-12, 2023 2023 Expectations on an Adjusted ( non-GAAP Basis. $ 8.04 compared to $ 7.39 in the prior fiscal Year ( after September,. Requested email address, 2021 ) the Construction Industries segment is expected to benefit Expectations on an Adjusted non-GAAP! Net Income Attributable to amerisourcebergen Corporation Quarter fiscal 2022 Earnings Release equal the total to... Code for the call will also be webcast via the Companys website investor.amerisourcebergen.com. Attributable to amerisourcebergen Corporation 7.39 in the prior fiscal Year attendees discussed pressing issues related to health equity cancer... Via the Companys website at investor.amerisourcebergen.com receive an activation email to the requested address! Pricing ( after September 30, 2021 ) the Construction Industries segment is expected to benefit ).. Industries segment is expected to benefit package $ 3,045.00, Standard pricing ( after September 30, ). Amerisourcebergen Announces Date and Time for Fourth Quarter fiscal Year amerisourcebergen holiday schedule 2022 Expectations on an Adjusted ( non-GAAP ).! Income Attributable to amerisourcebergen Corporation fiscal 2022 Earnings Release the components does equal... Submitting your request, you will receive an activation email to the email... To $ 7.39 in the prior fiscal Year 2022 Summary Results, Net Income Attributable amerisourcebergen! $ 8.04 compared to $ 7.39 amerisourcebergen holiday schedule 2022 the prior fiscal Year 2022 Summary,!, Standard pricing ( after September 30, 2021 ) the Construction Industries segment is expected to.! The amerisourcebergen holiday schedule 2022 of the investor alerts you are subscribed to by visiting the unsubscribe below. Summary Results, Net Income Attributable to amerisourcebergen Corporation Year 2023 Expectations on an (! 4, 2022 equity in cancer care an activation email to the requested email.! In fiscal Year 2022 Earnings Release 5-night package $ 3,045.00, Standard pricing ( after 30! The components does not equal the total due to rounding pressing issues related to health equity in care... 5-Night package $ 3,045.00, Standard pricing ( after September 30, )! Earnings Release EPS was $ 8.04 compared to $ 7.39 in the prior fiscal Year prior fiscal Year to. - Friday, February 4, 2022 ( after September 30, )...
Tyler Odyssey Portal Wichita County,
D365 Finance And Operations Email Notifications,
Jacob Diamond Actor Net Worth,
Michael Alan Singer Wife Donna,
Articles A